LuSeed’s DOME™ is a first-in-class, minimally invasive device for treating both Bifurcation and Sidewall brain aneurysms simply and safely. The device is designed for full compatibility with robotic systems.
It is our mission to provide a standard method of care, easily implemented by neuro radiologists at various experience levels, to improve both acute and long-term patient outcomes, mitigate potential complications, and optimize hospitals’ operational and financial burdens.
LuSeed Vascular is a pioneering medical technology startup that focuses on advancing neurovascular innovation. Our primary commitment is to create and introduce groundbreaking devices that bring about significant improvements in the treatment outcomes of brain aneurysms.
The company’s flagship product, LuSeed DOME™, is designed to provide neuro interventional physicians with the means to enable better care for their patients by enabling an intuitive, safe delivery and implantation at the target aneurysm, thanks to its unique geometry and characteristics.
The device provides a first of its kind approach for both Bifurcation and Sidewall Aneurysms, as its positioning in the aneurysm is agnostic to the catheter tip location at the implantation site.
Moreover, the device does not require dual anticoagulants due to minimized protrusion to parent arteries, mitigating related complications and enhancing long term patient safety.
Designed for both bifurcation and sidewall aneurysms.
Straightforward matching between the device and the aneurysm.
Tailored for ruptured cases via high mesh density.
Agnostic to catheter tip location and entrance angle at the implantation site.
Proximal marker protrusion-free geometry. No chronic usage of strong blood thinners required.
Implantation within minutes, reducing Cath-lab use time.
LuSeed Vascular is an innovative MedTech start-up dedicated to the development of cutting-edge solutions for treating neurovascular diseases.
The company’s flagship product, LuSeed DOME™ , is the world’s first “One and Done” aneurysm treatment device tailor-made for both bifurcation and sidewall cases.
LuSeed DOME™’s revolutionary braided mesh design enables a quick, easy delivery and positioning within the aneurysm from multiple angles, featuring a gradual, controlled, accurate deployment.
LuSeed DOME™ is designed to minimize protrusion to parent artery, mitigating the chronic need for high-risk Dual Antiplatelets.
Vast experienced in strategy building and fundraising for high risk high gain companies.
Amir is a team builder and leader, with a background of several leadership roles in the MedTech industry. Amir holds a Mechanical & Biomedical Engineer, (M.E, Technion, Summa Cum Laude) and has vast experience in percutaneous medical device design, bringing devices from ideation to clinical use. Additionally, Amir brings with him expert experience and deep knowledge of class iii medical devices.
A medical device leader with over twelve years of experience in complex multidisciplinary / class iii devices development.
Nitzan brings with him a proven track record of bringing medical devices from ideation to the market, combining fundraising (both equity and grants), team integration, regulatory and clinical development, IP creation and stakeholder management. Additionally, Nitzan holds a degree in Biomedical Engineering (M.E, Technion, Summa Cum Laude).
Broad experience in Medical Device areas related to quality (establishment and maintenance of QMS, work closely with different functions to assure product quality and continue improvement, leading of QA activities in design project), compliance (implementation of regulatory requirements and support in regulatory audits) and regulations for global registration (support in regulatory submissions including preparation of submission files and communication with regulatory authorities in different territories).
VP of Clinical Affairs at LuSeed Vascular, brings over 19 years of expertise in designing and managing national and international clinical studies across the Pharmaceutical and Medical Device industries, including FDA and EU submissions. Gali has successfully led clinical strategies to achieve product clearance, aligning study goals with business objectives and ensuring cross-functional collaboration.
A world-renowned endovascular neurosurgeon, and expert in treating wide neck cerebral aneurysms and neurovascular devices advanced testing and evaluation.
Professor Vitor Mendes-Pereira is Head of Endovascular Research at St. Michaels Hospital, Tornoto, Canada.
A mechanical Engineer with vast experience in the interventional domain.
Moshe manages the full life cycle of neurovascular medical products from concept to commercial launch. He also brings with him experience in optimizing design and production processes of commercial products.
Avia holds a bachelor’s degree in Biology and a master’s degree in Medical Sciences from Tel Aviv University with a focus in microbiology and clinical immunology.
CEO of Sanara Ventures and Sanara Capital.
Head of the Life Science Advisory Board at The Israel Export Institute.
Highly experienced in healthcare startups, corporate senior management & Venture Capital.
President Sanibel Capital, a seasoned neurovascular device executive.
Former CEO Vascular Dynamics. Former President and COO of Micrus, Endovascular. Vice-Chair of MIVI Neuro. Chairman of Cardiac-Tec.
Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital in Boston.
Dr. Edelman directs MIT’s Institute for Medical Engineering and Science (IMES) and Center for Clinical and Translational Research (CCTR) as well as the Harvard-MIT Biomedical Engineering Center (BMEC) – all dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease
Managing Director at Quadrant Private Equity.
Seasoned, high-profile investor, entrepreneur and executive, invested in numerous tech medical device companies carrying successful M&As / IPOs.
Head of Gandyr technology investment group – holds a vast track record in supporting and investing in impact and technology startups, in a variety of domains.
PhD in Physics. EVP & CTO, Sanara Ventures & Sanara Capital.
Possesses a strong academic and industry background in Healthtech R&D leadership and business development.